Evotec Takes The Lead On EU-Backed Antibiotic R&D Project
Executive Summary
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
You may also be interested in...
Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia
Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.